NCT06663137View on ClinicalTrials.gov

Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Non Muscle Invasive Bladder Cancer
Interventions
DRUG

NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

NDV01 is administered intravesically using a catheter.

Trial Locations (1)

4363007

RECRUITING

Relmada Site, Raanana

All Listed Sponsors
lead

Relmada Therapeutics, Inc.

INDUSTRY